Sitagliptin monoterapisi ile kombinasyon tedavilerinin karşılaştırılması
Author:
Publisher
Uludag Universitesi Tip Fakultesi Dergisi
Reference16 articles.
1. 1. Yokoh H, Kobayashi K, Sato Y, et al, on behalf of the SUCCESS Study Group. Eficacy and safety of the dipeptidil peptidase-4 inhibitor sitagliptin compared with alpha-glucısidase inhibitör in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with sitagliptin-1): A multicenter, randomizes, open-label, non-inferiority trial. J Diabetes Invest. 2015; 6: 182-91.
2. 2. Jameshorani M, Sayari S, Kiahashemi N, Motamed N. Comparative study on adding pioglitazone or sitagliptin to patients with type 2 diabetes mellitus insufficiently controlled with metformin. Open Access Maced J Med Sci. 2017; 5: 955-62.
3. 3. Nathan DM, Buse JB, Davidson MB, et al. American Diabetes Association; European Association for Study of Diabetes. Diabetes Care 2009; 32: 193-203.
4. 4. Abdul-Ghani MA, Puckett C, Triplitt C, et al. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficasy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. Diabetes Obes Metab 2015; 17: 267-75.
5. 5. Mikhail N. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential. Vasc Health Risk Manag 2008; 4: 1221-7.
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3